 Biomarkers, Tumor
"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 1 | 5 | | 1997 | 0 | 2 | 2 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 2 | 4 | 6 | | 2001 | 1 | 4 | 5 | | 2002 | 10 | 6 | 16 | | 2003 | 7 | 2 | 9 | | 2004 | 9 | 8 | 17 | | 2005 | 11 | 10 | 21 | | 2006 | 15 | 13 | 28 | | 2007 | 11 | 6 | 17 | | 2008 | 14 | 19 | 33 | | 2009 | 16 | 21 | 37 | | 2010 | 20 | 14 | 34 | | 2011 | 13 | 10 | 23 | | 2012 | 13 | 15 | 28 | | 2013 | 11 | 25 | 36 | | 2014 | 20 | 17 | 37 | | 2015 | 24 | 22 | 46 | | 2016 | 27 | 26 | 53 | | 2017 | 28 | 23 | 51 | | 2018 | 30 | 28 | 58 | | 2019 | 36 | 32 | 68 | | 2020 | 20 | 27 | 47 | | 2021 | 22 | 27 | 49 | | 2022 | 4 | 28 | 32 | | 2023 | 3 | 10 | 13 | | 2024 | 13 | 31 | 44 | | 2025 | 28 | 28 | 56 | | 2026 | 17 | 12 | 29 |
To return to the timeline, click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Yefet LS, Landry AP, Rogers CL, Wang JZ, Liu J, Patil V, Gui C, Ajisebutu A, Ellenbogen Y, Wei Q, Singh O, Mansouri S, Szot C, Jordan RC, Barani IJ, Straza MW, Shu HG, Pointer KB, Hunter G, Panet-Raymond V, Shi W, Perlow HK, Kavanagh BD, Gunter T, Robinson C, Pugh SL, Dicker AP, Mehta MP, Chakravarti A, Nassiri F, Aldape K, Zadeh G. Modern molecular profiling recontextualizes the NRG/RTOG 0539 trial and reveals hidden high-risk and radiotherapy-resistant meningiomas. Neuro Oncol. 2026 Jul 01; 28(7):1727-1740.
-
Fukuda R, Fujiwara Y, Maruyama T, Komohara Y. CD169-positive macrophages in lymph nodes and the tumor microenvironment: harnessing their biology for clinical diagnosis and anticancer therapeutic strategies. Front Immunol. 2026; 17:1852700.
-
Tesch ME, Zheng Y, Guzman-Arocho YD, Collins LC, Heng YJ, Tayob N, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges V, Come SE, Snow C, Winer EP, Mittendorf EA, Partridge AH. Association of Tumor-Infiltrating Lymphocyte Subtypes with Clinical Characteristics and Prognosis in Young Women with Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2026 Jun 01; 32(11):2268-2278.
-
Crowell C, Mankuzhy NP, Bennett J, Bandopadhayay P, Sturm D, Green AL, Gupta T, Chatterjee A, Epari S, Chinnaswamy G, Prasad M, Patel SH, MacNeil M, Vanan MI, Larouche V, Renzi S, Jones J, Perreault S, Mata-Mbemba D, Sangatsuda Y, Yoshimoto K, Lin E, Feddersen C, Cruz O, Pavon-Mengual M, Vizzini O, Zápotocký M, Popovacki A, Klawinski D, Hansford JR, Schlosser MP, Omene E, Alexander KL, Satgunaseelan L, Williams A, Yao K, Ronsley R, Cheng S, Ludlow L, Eisenstat D, Khuong-Quang DA, Tabouret E, André N, Matheson K, Chan A, Lim-Fat MJ, Lapointe S, Cayrol R, Coleman C, Juretic N, McThenia S, Khan S, Wright-Nadkarni M, Salloum R, Galvin RT, Sener U, Hawkins C, Imber BS, Karajannis MA, Jones DTW, Ligon KL, Jabado N, Erker C. Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study. Clin Cancer Res. 2026 Jun 01; 32(11):2243-2254.
-
Leseman CA, Bonomi AM, Schuitema J, Granieri S, Sällberg Chen M, Maker AV, Ateeb Z, Wood LD, Voermans RP, Marchegiani G, Del Chiaro M, Ket JCF, Lennon AM, Besselink MG. Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasm: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2026 Jun 01; 9(6):e2617587.
-
Bledsoe JR, Ferry JA, Li J, Sassoon A, Stonhill MA, Siegele B, Liang X, Dalton J, Mochel MC, Ivashkevich Y, Johari V, Sadigh S, Selove W, Sood S, Ward N, Woda B, Degar B, Feraco AM, Rowe J, Davies K, Al-Ibraheemi A, Amador C, Kovach AE, Fleming MD, Harris MH, Tsai HK. Recurrent SWI/SNF Deficiency Defines a Subset of Peripheral T-Cell Lymphoma With Distinct Clinicopathologic Features. Mod Pathol. 2026 Jul; 39(7):101015.
-
Paez R, Khalil TA, Forero Y, Woodhouse P, Antic S, Holmes H, Fremont RD, Brandt W, Chen H, Chen SC, Kaizer A, Shojaee S, Lentz RJ, Deppen SA, Barón AE, Grogan EL, Maldonado F. Assessing a biomarker platform for stratifying indeterminate pulmonary nodules, protocol for the SPOT IT randomized trial. Trials. 2026 May 12; 27(1).
-
Sherman ME, Etievant L, Vierkant RA, Winham SJ, Ruddy KJ, Pacheco-Spann L, Wickland DP, Cruz-Reyes N, Stallings-Mann M, Radisky D, Thompson EA, Kachergus JM, Shi J, Rosenberg SM, Snow C, Kirkner GJ, Schapira L, Peppercorn JM, Come S, Borges VF, Warner E, Collins LC, Partridge AH, Pfeiffer RM. Postpartum breast cancer: evidence for a distinct phenotype. J Natl Cancer Inst. 2026 May 01; 118(5):926-936.
-
Wong EYT, Damle SR, Shiu KK, Cohen SA, Lieu CH. Immunotherapy in Localized Colorectal Cancer: Current Practice and Future Directions. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520600.
-
Nie Y, Staley A, Hinz TK, Perez-Johnston R, Merrick DT, Yang MC, Davies KD, Bunn PA, Aisner DL, Camidge DR, Schenk EL, Heasley LE, Patil T. High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors. Clin Lung Cancer. 2026 Jun; 27(5):96-105.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|